The second cohort of patients received the once-off therapy at twice the dose (88 x 106 cells) to the first cohort of patients. In the first cohort, three of the four patients achieved disease stability at eight weeks. In the current cohort, two of the three patients achieved locally stable disease.
Safety of the therapy remains good, with this second cohort receiving the cells directly into the tumours but also in the CSF (intraventricular injection).
The company will now move on to the third cohort, whereby the dose will be increased by 150% to 220 x 106 cells. Progress of patients from the first cohort would also be beneficial information to investors.
Chimeric Therapeutics is capitalised at $70 million.
Bioshares Recommendation: Speculative Buy Class B
Disclaimer:
Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than $100 are not disclosed.
